At Baxter, we truly understand the challenges you face. As a leader in the manufacturing of medical devices for over 80 years, we’ve been committed to advancing dialysis and hemodialysis treatment in ground-breaking and meaningful ways. We lead the way with innovative products, comprehensive support, and in-depth training across the lifecycle of our products. At Baxter, we don’t believe in delivering the same standardized therapy to all patients, but instead provide choices to select the therapy and treatment modality that is right for both patients and clinic.
Introducing EXPANDED HEMODIALYSIS [HDx] enabled by Theranova
Theranova, the next evolution in hemodialysis, brings us a step closer to the natural kidney by superior removal of conventional/large middle molecular (500-45,000 Da) uremic toxins, compared to traditional hemodialysis.1-4
With HDx therapy, efficient removal of these toxins may improve patient reported kidney disease quality of life outcomes including: symptom burden, Restless Leg Syndrome (RLS) criteria and uremic pruritus.1,4,5
Baxter's next-generation hemodialysis machine
Since first introduced in 1967, the Artificial Kidney Family has demonstrated a proven track record in dialysis care
and significantly improved the field through groundbreaking technology and first-to-market advancements. The AK 98 continues this tradition and legacy.
PENDING 510K CLEARANCE. NOT CURRENTLY FOR SALE IN THE US.
Working with Baxter Healthcare
We offer a full range of hemodialysis-specific products and services to help meet the needs of your HD patients, your staff, and your clinic.
Certified Technical Support
With more than 800 field service engineers supporting dialysis providers in over 60 countries, troubleshooting and assistance are always within reach.
We offer hands-on hemodialysis training at your facility, with continuous learning opportunities throughout the life of your Baxter products.
ICHD Facts & Figures
There are 726,000 ESRD patients in the US6
88% of ESRD patients are treated by In-Center Hemodialysis6
The US ESRD & ICHD population grows 3% grows annually6